JP2022001838A5 - - Google Patents

Download PDF

Info

Publication number
JP2022001838A5
JP2022001838A5 JP2020106421A JP2020106421A JP2022001838A5 JP 2022001838 A5 JP2022001838 A5 JP 2022001838A5 JP 2020106421 A JP2020106421 A JP 2020106421A JP 2020106421 A JP2020106421 A JP 2020106421A JP 2022001838 A5 JP2022001838 A5 JP 2022001838A5
Authority
JP
Japan
Prior art keywords
synaptic dysfunction
darps
concentration
disease
caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020106421A
Other languages
English (en)
Japanese (ja)
Other versions
JP7244931B2 (ja
JP2022001838A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2020106421A external-priority patent/JP7244931B2/ja
Priority to JP2020106421A priority Critical patent/JP7244931B2/ja
Priority to EP21826587.4A priority patent/EP4170032A4/en
Priority to CN202180043301.0A priority patent/CN115702352A/zh
Priority to US18/002,332 priority patent/US20230349925A1/en
Priority to PCT/JP2021/023135 priority patent/WO2021256550A1/ja
Publication of JP2022001838A publication Critical patent/JP2022001838A/ja
Publication of JP2022001838A5 publication Critical patent/JP2022001838A5/ja
Priority to JP2023032921A priority patent/JP7620340B2/ja
Publication of JP7244931B2 publication Critical patent/JP7244931B2/ja
Application granted granted Critical
Priority to JP2024231531A priority patent/JP2025060925A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020106421A 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法 Active JP7244931B2 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2020106421A JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
PCT/JP2021/023135 WO2021256550A1 (ja) 2020-06-19 2021-06-18 シナプス機能不全に起因する疾病、又はシナプス機能不全を付随する疾病の判定方法
CN202180043301.0A CN115702352A (zh) 2020-06-19 2021-06-18 因突触功能不全引起的疾病或附带突触功能不全的疾病的判定方法
US18/002,332 US20230349925A1 (en) 2020-06-19 2021-06-18 Method for determining disease caused by synaptic dysfunction or disease accompanied by synaptic dysfunction
EP21826587.4A EP4170032A4 (en) 2020-06-19 2021-06-18 METHOD FOR DETERMINING A DISEASE CAUSED BY SYNAPTIC DYSFUNCTION OR A DISEASE ACCOMPANIED BY SYNAPTIC DYSFUNCTION
JP2023032921A JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2024231531A JP2025060925A (ja) 2020-06-19 2024-12-27 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020106421A JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023032921A Division JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Publications (3)

Publication Number Publication Date
JP2022001838A JP2022001838A (ja) 2022-01-06
JP2022001838A5 true JP2022001838A5 (https=) 2022-06-14
JP7244931B2 JP7244931B2 (ja) 2023-03-23

Family

ID=79244367

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020106421A Active JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2023032921A Active JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2024231531A Pending JP2025060925A (ja) 2020-06-19 2024-12-27 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023032921A Active JP7620340B2 (ja) 2020-06-19 2023-03-03 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2024231531A Pending JP2025060925A (ja) 2020-06-19 2024-12-27 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法

Country Status (5)

Country Link
US (1) US20230349925A1 (https=)
EP (1) EP4170032A4 (https=)
JP (3) JP7244931B2 (https=)
CN (1) CN115702352A (https=)
WO (1) WO2021256550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4632384A1 (en) * 2022-12-05 2025-10-15 AlzMed, Inc. Method for determining cognitive dysfunction stage
WO2025177848A1 (ja) * 2024-02-22 2025-08-28 アルメッド株式会社 ドレブリン由来のｉＭＡＤＰ、ｉＭＡＤＰを測定する方法及びｉＭＡＤＰの測定用キット

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4568463B2 (ja) * 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP2003180361A (ja) * 2001-12-13 2003-07-02 Japan Science & Technology Corp ｓ−ドレブリンＡ
WO2004007674A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal and retinal gene expression patterns
JP4550530B2 (ja) * 2004-09-03 2010-09-22 独立行政法人科学技術振興機構 シナプス成熟障害モデル動物
JP2016040540A (ja) * 2014-08-13 2016-03-24 国立大学法人群馬大学 ドレブリンａ及びドレブリンｅの特異的定量法
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
JP7111494B2 (ja) 2018-04-05 2022-08-02 グローリー株式会社 光検出センサ、光検出装置、シート類処理装置および光検出方法
JP7324994B2 (ja) * 2018-05-08 2023-08-14 アルメッド株式会社 ドレブリンに特異的に結合するペプチド、及びそのペプチドを用いたドレブリンの検出方法
CN109490527B (zh) * 2018-11-08 2020-01-21 温州医科大学 Dbn1蛋白在制备神经变性疾病诊断药物中的应用
JP7536240B2 (ja) * 2019-03-13 2024-08-20 国立大学法人群馬大学 Ｎｍｄａ受容体阻害活性のハイスループット評価方法
JP7416399B2 (ja) * 2019-10-08 2024-01-17 アルメッド株式会社 アルツハイマー病モデル非ヒト動物及びその製造方法

Similar Documents

Publication Publication Date Title
Gindele et al. Intermittent exposure to whole cigarette smoke alters the differentiation of primary small airway epithelial cells in the air-liquid interface culture
Majbour et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
US20190219578A1 (en) Dectection of exosomes and exosomal biomarkers for the diagnosis and prognosis of diseases and disorders
Ikezumi et al. Identification of alternatively activated macrophages in new‐onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion
Duran-Aniotz et al. Aggregate-depleted brain fails to induce Aβ deposition in a mouse model of Alzheimer's disease
Berankova et al. Structural changes in the bronchial mucosa of young children at risk of developing asthma
TW201606307A (zh) 阿茲海默症及其他神經退化性疾病之生物標記及診斷方法
JP7495878B2 (ja) 神経変性状態を処置するための医薬を開発するための方法
US11280783B2 (en) Devices and methods related to airway inflammation
Oshio et al. Dermatophagoides farinae extract induces severe atopic dermatitis in NC/Nga mice, which is effectively suppressed by the administration of tacrolimus ointment
JP7732015B2 (ja) アルファ－シヌクレインアッセイ
JP2022001838A5 (https=)
Mitrano et al. Olfactory dysfunction in the 3xTg-AD model of Alzheimer’s disease
WO2012004566A1 (en) Method for diagnosis
Wei et al. Reduced glutamate release in adult BTBR mouse model of autism spectrum disorder
Samaroo et al. High throughput object-based image analysis of β-amyloid plaques in human and transgenic mouse brain
Slemann et al. Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies
JP2025060925A (ja) シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
Duan et al. CX3CR1+/UCHL1+ microglial extracellular vesicles in blood: a potential biomarker for multiple sclerosis
Marshe et al. A factor-based analysis of individual human microglia uncovers regulators of an Alzheimer-related transcriptional signature
Costa et al. Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease
CN111971561A (zh) 同种异体移植受体分型的生物标记物
CA2869571A1 (en) Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof
CN118389662A (zh) 一种有效区分不同类型抑郁障碍相关疾病的生物标志物及其用途
JP2015524551A (ja) アルツハイマー病及び軽度認知障害関連トロポミオシンアイソフォーム